Strategic partnerships Active collaborations with AbbVie, Takeda, and Lilly indicate a strong appetite from large pharma to leverage AI-driven biology insights. Leverage these relationships to identify adjacent targets, expand into new pipeline programs, and propose co-development or expanded access to the Biology GPU across additional disease areas.

AI to cell advantage Biology GPU enables visualized, AI-scale experiments inside cells, offering a differentiator for target discovery, pathway signature identification, and compound optimization. Position this as a means to accelerate early-stage hit finding and mechanism-of-action validation for potential customers seeking faster R&D timelines.

Scale-ready platform A 2B+ proprietary cellular pathway image training set and a Visual Biology Model suggest readiness to scale across discovery programs. Offer enterprise-grade deployment options, data localization, and governance features to large pharma customers with multi-program needs and strict regulatory requirements.

Financial traction Annual revenue in the range of tens of millions demonstrates market interest and credibility. Use revenue benchmarks to approach mid-to-large biotech and pharma buyers with clearly defined ROI by reduced experiment cycles, improved target confidence, and faster preclinical decision-making.

Industry positioning Position Anima Biotech as a niche leader in AI-driven modulation of mRNA biology and pathway-level reasoning. Target biotech firms and CROs focused on oncology, immunology, and neurological targets, offering collaboration models, joint development opportunities, and access to the Biology GPU to de-risk and accelerate their discovery workflows.